key: cord-1044102-wq2zz4zt
authors: Sharma, Ketaki; Koirala, Archana; Nicolopoulos, Katrina; Chiu, Clayton; Wood, Nicholas; Britton, Philip N.
title: Vaccines for COVID-19: where do we stand in 2021?
date: 2021-07-12
journal: Paediatr Respir Rev
DOI: 10.1016/j.prrv.2021.07.001
sha: 3f31c8bc73271e11a625f4283ed723236a4b6d94
doc_id: 1044102
cord_uid: wq2zz4zt

As of July 2021, over 3 billion doses of a COVID-19 vaccines have been administered globally, and there are now 19 COVID-19 vaccines approved for use in at least one country. Several of these have been shown to be highly effective both in clinical trials and real-world observational studies, some of which have included special populations of interest. A small number of countries have approved a COVID-19 vaccine for use in adolescents or children. These are laudable achievements, but the global vaccination effort has been challenged by inequitable distribution of vaccines predominantly to high income countries, with only 0.9% of people in low-income countries having received at least one dose of a COVID-19 vaccine. Addressing this inequity is of critical importance and will result in better control of SARS-CoV-2 globally. Other challenges include: the reduced protection from COVID-19 vaccines against some strains of SARS-CoV-2, necessitating the development of variant specific vaccines; and uncertainties around the duration of protection from vaccine-induced immunity.

As of early July 2021, over 181 million cases of COVID-19 and over 3.9 million deaths have been reported globally. (1) The impacts of the pandemic have been felt unequally around the world, with varying public health strategies leading to different epidemic trajectories.(2) Many countries are struggling with successive waves of COVID-19, and the goal of global elimination of SARS-CoV-2 has been abandoned and replaced with that of transition to endemicity.

A year ago, over 100 COVID-19 vaccines were under development, but none were approved for use.(3) Within 12 months several highly effective COVID-19 vaccines have achieved widespread use with over 3.04 billion doses administered, although unfortunately not equitably distributed. Of the global population, 23.4% have received at least one dose of a COVID-19 vaccine while only 0.9% of people in low-income countries have done so. (4) Other factors that will influence the success of the global COVID-19 vaccination effort include the duration of immunity provided by vaccination, vaccine effectiveness against variant strains of SARS-CoV-2, and the impact of vaccines on transmission. Additionally, rare but serious adverse events associated with specific COVID-19 vaccines have been identified since their widespread use, in one case resulting in limitations to use in several countries.

There are currently 105 COVID-19 vaccines in clinical trials, and 184 in pre-clinical development. (5) The majority of candidate vaccines target part or all of the SARS-CoV-2 spike protein. A variety of platform technologies are being studied, including protein subunit (32 candidates), viral vector (21 candidates), RNA (17 candidates), inactivated (16 candidates) and DNA (10 candidates). Only two live attenuated COVID-19 vaccines are in clinical trials, both in phase I. mRNA nucleic acid vaccines and viral vector vaccines are newer technologies, and have been relatively fast to develop and manufacture, in part because developers required access only to the genome sequence of SARS-CoV-2 rather than physical samples of the virus. A programmatic limitation with mRNA vaccines has been their requirement for ultra-cold storage, making distribution logistically challenging. However, progress is being made; a phase I trial of a fridge-stable mRNA vaccine (mRNA-1283, Moderna) is now underway, and it is possible that lyophilised formulations will be available in the future. (6, 7) Vaccines in use As of June 2021, 19 unique COVID-19 vaccines have regulatory approval in at least one country, as shown in Table 1 . Most of these have provisional or emergency authorisation only, often on the basis of interim phase III trial results, and in some cases without any available published clinical trial results.

Six unique vaccines have received Emergency Use Listing (EUL) by the World Health Organization (WHO), and several others are currently under review.(8) WHO Emergency Use Listing is a prerequisite for COVAX Facility vaccine supply, COVAX being an initiative of the Coalition of Epidemic Preparedness Innovations (CEPI), the Global Vaccine Alliance (Gavi) and the WHO, focussed on accelerating the development and manufacture of COVID-19 vaccines and ensuring equitable access globally through a shared procurement mechanism.

Vaccine efficacy measures the proportionate reduction (relative risk reduction) of specific outcomes of interest among vaccinated persons compared to unvaccinated persons in "ideal" conditions, as in a phase III randomised controlled clinical trial. Vaccine effectiveness refers to the relative risk reduction of the same outcomes but in populations under real-world conditions, as in observational studies ('phase IV' studies). For several currently used COVID-19 vaccines, efficacy or effectiveness data are only available from interim analyses of phase III trials, or preprint publications.

Phase III results have been published or announced for 13 of the COVID-19 vaccines currently in use, with reported efficacy ranging from 50% -95% for those with published data. Table 1 presents a summary of efficacy and effectiveness for the vaccines currently in use, including preprint or announced results, where published data are not available. Many COVID-19 vaccines show excellent efficacy against severe illness, even if efficacy against symptomatic illness is less impressive. Emerging evidence suggests that some COVID-19 vaccines also reduce the risk of asymptomatic illness, and therefore may reduce transmission of SARS-CoV-2.

The available phase IV effectiveness data generally correlate well with clinical trial findings, as shown in Table 1 . This is reassuring since many countries are prioritising vaccinating population groups who are excluded or under-represented in clinical trials, such as older adults and people with medical comorbidities, who may have reduced immune responses to vaccines.

In the absence of direct head-to-head studies, efficacy cannot yet be directly compared between different COVID-19 vaccines for a multitude of reasons, including differing settings, inclusion criteria and outcome definitions within the trials, and varying rates and dominant strains of SARS-CoV-2 in the countries where the trials were undertaken.

It is too early to know the duration of protection afforded by the currently available vaccines (or indeed by natural immunity). A correlate of protection (CoP) would facilitate more rapid evaluation of newer vaccines (including those focussed on variants, and in special populations), and of the need for and timing of vaccine booster doses. No CoP has yet been established, although neutralising antibody titres appear to be highly predictive of vaccine efficacy.(9)

The majority of children with COVID-19 have mild or asymptomatic illness, though severe illness has been described, and is more likely in children with co-morbidities or in infants aged under 3 months.(10) COVID-19 is also associated with a rare post-infectious syndrome called multisystem inflammatory syndrome (MIS-C) or Paediatric Multisystem Inflammatory Syndrome -Temporally Associated with SARS-CoV-2 (PIM-TS), which exclusively affects children and leads to intensive care admission in the majority of cases. (11) In addition to protection against these severe outcomes, vaccination of children will be a critical step in achieving herd immunity against SARS-CoV-2.

BNT162b2 (Pfizer; BioNTech) was the first COVID-19 to be approved in children (aged 12-15), initially in Canada and now in several other countries. (12) In an ongoing phase III trial of 2260 adolescents aged 12 to 15 years, BNT162b2 was shown to be safe and high effective (efficacy 100% (95% CI, 75.3 to 100)).(13) A trial of this vaccine in children aged 6 months to 11 years has commenced.(14) More recently, Sinovac's mRNA vaccine CoronaVac has been approved for use in children aged ≥ 3 years in China, on the basis of a phase I/II trial showing acceptable safety and strong immune responses in 100% of participants in the higher dose group. (15, 16) Vaccine efficacy of 100% has been announced for Moderna's mRNA-1273 in adolescents aged 12-17 years, and its approval in this age group is anticipated. (17) Moderna have also announced a trial in children aged 6 month to 12 years is planned. (17) Variants Multiple mutant strains of SARS-CoV-2 are circulating globally, some of which have been designated by the World Health Organization as 'variants of interest' or 'variants of concern'.(18) The latter (currently 4 identified) are associated with significant features such as increased transmissibility, increased virulence or decrease in effectiveness of public health measures or vaccines. (18) Table 2 summarises available data on the immunogenicity, efficacy or effectiveness of COVID-19 vaccines against the four variants of concern of SARS-CoV-2. Protection may be lower against some strains e.g. Beta, or B.1.351, first identified in South Africa. Few studies have reported on protection against severe illness or hospitalisation, however it is promising to note that AZD1222 (University of Oxford; AstraZeneca) and BNT162b2 both appear to provide excellent protection against hospitalisation due to the delta strain. (19) The next phase of COVID-19 vaccine development involves variant-specific and multi-valent COVID-19 vaccines, which may be utilised as booster doses to those already vaccinated or for primary vaccination courses. Candidate vaccines targeting the Beta (B.1.351) strain include BNT162b2s01 (Pfizer; BioNTech), currently in phase III trial, mRNA-1273.351 (Moderna) and the bivalent mRNA-1273.211 (Moderna), both registered to enter phase III trials this year.

Heterologous schedules involving different vaccines for the initial and booster doses have been required for a variety of reasons, including global supply constraints and safety issues relating to the vaccine used for the first dose.

Early safety and immunogenicity data of such schedules are emerging. A study involving 363 participants aged ≥ 50 years in the UK showed an increase in systemic reactogenicity (i.e. fever, chills, fatigue, headache, joint pain, malaise, and muscle ache) after the second dose in participants receiving a dose each of AZD1222 and BNT162b2 4 weeks' apart, compared to homologous schedules, and regardless of which vaccine was given first. Reassuringly, these symptoms were short lived. (20) In a follow up preprint paper, the authors reported that regardless of which vaccine was given first, a mixed schedule resulted in a higher geometric mean concentration (GMC) of anti-spike IgG at 28 days post-boost, compared to a homologous schedule of AZD1222.(21) A German preprint study reported no difference in reactogenicity and equal/improved immunogenicity in 26 individuals aged 25-46 given AZD1222 followed by BNT162b2 8 weeks apart compared to two doses of BNT162b2. (22) These early data suggest that mixed schedules are likely to be acceptable, and may even be superior, compared to homologous schedules.

Given the speed and scale of the COVID-19 vaccine rollout, vaccine safety has been closely monitored by regulators and has been the subject of intense media scrutiny. Although safety outcomes are a major focus of clinical trials, these trials are underpowered to detect extremely rare adverse events, which instead are typically detected in post-licensure safety surveillance. It is therefore unsurprising that some COVID-19 vaccines have been found to be associated with very rare but in some cases serious adverse events, some of which have had programmatic implications.

A rare, newly identified syndrome now called thrombosis with thrombocytopenia syndrome (TTS) has been reported in association with two viral vector vaccines, AZD1222 and Ad26.COV2.S (Janssen; Johnson & Johnson), suggesting a potential class effect. (23) (24) (25) This rare immune-mediated disorder involves thrombosis in varying locations, accompanied by thrombocytopenia. To date TTS has not been reported in association with any other viral vector vaccine. TTS appears to be more common in younger adults, leading several countries to restrict its use to older age groups with varying age cutoffs, and in some cases leading to the use of heterologous schedules to complete vaccination courses following a first dose of AZD1222. (26) More recently, myocarditis has been reported at higher than expected rates in adults and adolescents who have received an mRNA COVID-19 vaccine (BNT162b2 or mRNA-1273) in the United States and Israel (27, 28) . This safety signal continues to be investigated by regulators and to date has not led to any restrictions on the use of mRNA vaccines.

Investments by several high-income countries accelerated the vaccine development process, and enabled these countries to secure their own vaccine supply. The largest of these is Operation Warp Speed, a US public-private partnership which invested US$18 billion in into a portfolio of 8 vaccine candidates, all obliged to enter into product delivery commitments with the USA. (29) Equitable global vaccine distribution would provide the best chance of suppressing new variants, generating herd immunity, and eventually bringing the pandemic to an end. COVAX aimed to provide a central negotiating system between countries and vaccine developers, and to distribute the vaccines globally in an equitable manner, starting with enough doses for 20% of each participating country's population. Further distribution would be based on measures of need (burden of disease, universal health coverage service index, health system saturation, high risk groups for COVID-19).

High income countries invested in COVAX while maintaining their direct bilateral deals, often securing enough doses to vaccinate their population several times over. This parallel investment and acquisition process has enabled vaccine access and roll-out to occur most rapidly in the USA and European countries, but with the consequence of making fewer doses available for COVAX and for low middle income countries (LMIC). (30) This has demonstrably reinforced global inequalities, as demonstrated in Figure 1 . 

The past 18 months have seen extraordinary scientific achievements that have yielded a growing global portfolio of effective vaccines against COVID-19. Several vaccines are confirmed to be safe and effective both in healthy individuals and in special populations (such as older adults or adolescents), particularly against severe illness. These findings have been replicated in real-world studies in various countries. Protection appears to be reduced against some variant strains, and variant-specific vaccines are already under development.

Unfortunately, despite the proactive efforts of the COVAX facility and other bodies to ensure equitable vaccine distribution, the supply of COVID-19 vaccines has been predominantly to high income countries, resulting in very low vaccination rates in low-and middle-income countries Addressing this inequity will benefit all by eventually leading to better control of SARS-CoV-2. All countries should be reminded that COVID-19 anywhere is a risk of COVID-19 everywhere. Neutralising antibodies decreased 1.6-fold compared to wild-type strain (85) 

SARS-CoV-2 elimination, not mitigation, creates best outcomes for health, the economy, and civil liberties

Vaccines for COVID-19: The current state of play

Oxford Martin School, The University of Oxford, Global Change Data Lab

World Health Organization. COVID-19 vaccine tracker and landscape

A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19

Addressing the Cold Reality of mRNA Vaccine Stability

Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

Risk Factors for Severe COVID-19 in Children

Multi-system inflammatory syndrome in children & adolescents (MIS-C): A systematic review of clinical features and presentation

COVID-19 vaccines for children younger than 12 years: are we ready? Lancet Infect Dis

Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents

Pfizer-BioNTech Announce Positive Topline Results of Pivotal COVID-19 Vaccine Study in Adolescents

Sinovac's COVID-19 vaccine gains China nod for emergency use in kids, adolescents. Reuters

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial

Moderna Announces TeenCOVE Study of its COVID-19 Vaccine in Adolescents Meets Primary Endpoint and Plans to Submit Data to Regulators in Early June

World Health Organization. Tracking SARS-CoV-2 variants

Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant PHE (preprint)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. The Lancet

Safety and Immunogenicity Report from the Com-COV Study -a Single-Blind Randomised Non-Inferiority Trial Comparing Heterologous And Homologous Prime-Boost Schedules with An Adenoviral Vectored and mRNA COVID-19 Vaccine

Social Science Research Network

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study. medRxiv

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Covid-19: How AstraZeneca lost the vaccine PR war

Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines

Symptomatic acute myocarditis in seven adolescents following Pfizer-BioNTech COVID-19 vaccination

Operation Warp Speed: implications for global vaccine security

A beautiful idea: how COVAX has fallen short. The Lancet

COVID-19 vaccine doses administered per 100 people

World Health Organization. G7 announces pledges of 870 million COVID-19 vaccine doses, of which at least half to be delivered by the end of 2021

Bridge Consulting. China COVID-19 Vaccine Tracker

Can Cuba beat COVID with its homegrown vaccines? Nature

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. The Lancet

Pfizer-BioNTech Vaccine Effectiveness Against SARS-CoV-2 Infection: Findings From a Large Observational Study in Israel. Saciuk Yaki Kertes Jennifer Mandel Micha Hemo Beatriz Shamir Stein Naama Zohar Anat Ekka Pfizer-BioNTech Vaccine Eff SARS-CoV-2 Infect Find Large Obs Study Isr Available SSRN Httpsssrncomabstract3868853 Httpdxdoiorg102139ssrn3868853

Impact of vaccination on new SARS-CoV-2 infections in the UK. medRxiv

Effectiveness of the BNT162b2 Covid-19 Vaccine against the B. 1.1. 7 and B. 1.351 Variants

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. The Lancet

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. Reply

The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data

Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers -Eight

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis [Press release

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. The Lancet

Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19

COVID-19) vaccine: Background document to the WHO Interim recommendations for use of Ad26.COV2.S (COVID-19) vaccine

Real-World Effectiveness of Ad26.COV2.S Adenoviral Vector Vaccine for COVID-19

Social Science Research Network

FDA Briefing Document. Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19

Accepts the Application for Conditional Marketing Authorization of CanSinoBIO's COVID-19 Vaccine ConvideciaTM

Safety and efficacy of an rAd26 and rAd5 vectorbased heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. The Lancet

The Gamaleya National Center. SPUTNIK V DEMONSTRATES 97.6% EFFICACY ACCORDING TO ANALYSIS OF DATA FROM 3.8 MILLION VACCINATED PERSONS IN RUSSIA MAKING IT THE MOST EFFICIENT COVID-19 VACCINE IN THE WORLD

The Gamaleya National Center. SPUTNIK V HAS DEMONSTRATED 97.8% EFFICACY AGAINST COVID CASES AND 100% EFFICACY AGAINST SEVERE CASES OF COVID IN UAE

3% Efficacy And High Safety Profile During The Vaccination Campaign In Bahrain

Sputnik Light vaccine (the first component of Sputnik V vaccine) demonstrates 78.6-83.7% efficacy among the elderly in Argentina

Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial

Efficacy and Safety of a COVID-19 Inactivated Vaccine in Healthcare Professionals in Brazil: The PROFISCOV Study

Social Science Research Network

Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19

Performance of vaccination with CoronaVac in a cohort of healthcare workers (HCW) -preliminary report. medRxiv

Bharat Biotech Announces Phase 3 Results of COVAXIN®: India's First COVID-19 Vaccine Demonstrates Interim Clinical Efficacy of 81% [Press Release

Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN®; Demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe COVID-19 disease

Sovereign 02 shows 62 percent efficacy in its two-dose schedule

Vaccine candidate Abdala showed an efficacy of 92.28% in his three-dose schedule

Effectiveness of COVID-19 vaccines against the B.1.617.2 variant. medRxiv

Single-dose mRNA vaccine effectiveness against SARS-CoV-2, including P.1 and B.1.1.7 variants: a test-negative design in adults 70 years and older in British Columbia

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. The Lancet

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccineinduced sera

Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2. bioRxiv

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization. bioRxiv

SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. The Lancet

Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant (preprint)

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. medRxiv

A Study In Argentina Confirms Sputnik V Highly-Effective Against Manaus Variant of Coronavirus

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization

Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv

Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac

Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study. medRxiv

Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant-associated epidemic of COVID-19 in Brazil: A test-negative case-control study. medRxiv

Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum. bioRxiv

Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152. bioRxiv